Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vector-mediated drug delivery to the brain
Autore:
Pardridge, WM;
Indirizzi:
Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 Los Angeles, CA 90095 USA
Titolo Testata:
ADVANCED DRUG DELIVERY REVIEWS
fascicolo: 2-3, volume: 36, anno: 1999,
pagine: 299 - 321
SICI:
0169-409X(19990405)36:2-3<299:VDDTTB>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
BARRIER IN-VIVO; SERUM NUCLEASE DEGRADATION; HUMAN INSULIN-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; MONOCLONAL-ANTIBODY; TRANSFERRIN RECEPTOR; ANTISENSE OLIGONUCLEOTIDES; RAT-BRAIN; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE; AMYLOID PEPTIDE;
Keywords:
blood-brain barrier; insulin receptor; Alzheimer's disease; drug delivery; pharmacokinetics; avidin; biotin;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
89
Recensione:
Indirizzi per estratti:
Indirizzo: Pardridge, WM Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 A 90095 USA
Citazione:
W.M. Pardridge, "Vector-mediated drug delivery to the brain", ADV DRUG DE, 36(2-3), 1999, pp. 299-321

Abstract

Vector-mediated drug delivery to the brain employs the chimeric peptide technology, wherein a non-transportable drug is conjugated to a blood-brain barrier (BBB) transport vector. The latter is a modified protein or receptor-specific monoclonal antibody that undergoes receptor-mediated transcytosisthrough the BBB in vivo. Conjugation of drug to transport vector is facilitated with either chemical linkers, avidin-biotin technology, polyethylene glycol linkers, or liposomes. Multiple classes of therapeutics have been delivered to the brain with the chimeric peptide technology, including peptide-based pharmaceuticals, such as a vasoactive intestinal peptide analog or neurotrophins such as brain-derived neurotrophic factor, antisense therapeutics including peptide nucleic acids, and small molecules incorporated within Liposomes. The successful delivery of a drug through the BBB in vivo requires special molecular formulation of the drug. Therefore, it is importantto merge central nervous system drug discovery and delivery as early as possible in the overall CNS drug development process. (C) 1999 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 13:47:56